Gilead plays a central role in developing single tablet regimens – with one pill once a day, patients can take all of their medication in each dose.
Our liver disease programs focus on expanding treatment options for chronic hepatitis B and C.
Our scientists are applying new knowledge about how cancers grow and spread to potentially enhance and improve cancer therapy.
Our medicines aim to help patients with cardiovascular disease return to their daily activities, and we are exploring potential new indications.
We research and develop treatments for serious respiratory conditions such as influenza, cystic fibrosis and other diseases of the lungs.
Gilead medicines treat severe fungal and parasitic infections, and address vision loss caused by degenerative eye diseases.
President and CEO John Milligan offers perspective on plans for authorized generic versions of its leading HCV medications. Read more here.
Access earnings press release, webcast link and slides for Gilead’s second quarter 2018 financial results. View materials.
October 11, 2018 Gilead Sciences to Release Third Quarter 2018 Financial Results on Thursday, October 25, 2018